|
|
Blood, 1 April 2004, Vol. 103, No. 7, pp. 2738-2743.
Prepublished online as a Blood First Edition Paper on October 9, 2003; DOI 10.1182/blood-2003-06-2031.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents
Mark S. Cragg, and
Martin J. Glennie
From the Tenovus Research Laboratory, Cancer Sciences Division, School of Medicine, General Hospital, Southampton, United Kingdom.
Despite the success of anti-CD20 monoclonal antibody (mAb) in the treatment of lymphoma, there remains considerable uncertainty about their mechanism(s) of action. Here, we show that certain of these reagents (rituximab and 1F5), which redistribute CD20 into membrane rafts, are bound efficiently by C1q, deposit C3b, and result in complement-dependent cytotoxicity (CDC). This activity is important in vivo, because complement depletion using cobra venom factor (CVF) markedly reduced the efficacy of rituximab and 1F5 in 2 lymphoma xenograft models. However, complement depletion had no effect on the potent therapeutic activity of B1, a mAb that does not redistribute CD20 into membrane rafts, bind C1q, or cause efficient CDC. Equivalent immunotherapy also occurred in the presence or absence of natural killer (NK) cells. Perhaps most surprising was the observation that F(ab')2 fragments of B1 but not 1F5 were able to provide substantial immunotherapy, indicating that non-Fc-dependent mechanisms are involved with B1. In accordance with this, B1 was shown to induce much higher levels of apoptosis than rituximab and 1F5. Thus, although complement is important for the action of rituximab and 1F5, this is not so for B1, which more likely functions through its ability to signal apoptosis. (Blood. 2004;103:2738-2743)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. W. Pawluczkowycz, F. J. Beurskens, P. V. Beum, M. A. Lindorfer, J. G. J. van de Winkel, P. W. H. I. Parren, and R. P. Taylor
Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX
J. Immunol.,
July 1, 2009;
183(1):
749 - 758.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Mishima, N. Sugimura, Y. Matsumoto-Mishima, Y. Terui, K. Takeuchi, S. Asai, D. Ennishi, H. Asai, M. Yokoyama, K. Kojima, et al.
An Imaging-Based Rapid Evaluation Method for Complement-Dependent Cytotoxicity Discriminated Clinical Response to Rituximab-Containing Chemotherapy
Clin. Cancer Res.,
May 15, 2009;
15(10):
3624 - 3632.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Schliemann, A. Palumbo, K. Zuberbuhler, A. Villa, M. Kaspar, E. Trachsel, W. Klapper, H. D. Menssen, and D. Neri
Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2
Blood,
March 5, 2009;
113(10):
2275 - 2283.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Minard-Colin, Y. Xiu, J. C. Poe, M. Horikawa, C. M. Magro, Y. Hamaguchi, K. M. Haas, and T. F. Tedder
Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage Fc{gamma}RI, Fc{gamma}RIII, and Fc{gamma}RIV
Blood,
August 15, 2008;
112(4):
1205 - 1213.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Meyer zum Buschenfelde, Y. Feuerstacke, K. S. Gotze, K. Scholze, and C. Peschel
GM1 Expression of Non-Hodgkin's Lymphoma Determines Susceptibility to Rituximab Treatment
Cancer Res.,
July 1, 2008;
68(13):
5414 - 5422.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Koslowski, U. Sahin, K. Dhaene, C. Huber, and O. Tureci
MS4A12 Is a Colon-Selective Store-Operated Calcium Channel Promoting Malignant Cell Processes
Cancer Res.,
May 1, 2008;
68(9):
3458 - 3466.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Simon, T. Newsom-Davis, M. E. F. Frayne, P. F.-T. Ch'en, A. J. McMichael, and G. R. Screaton
Generation of tumour-rejecting anti-carbohydrate monoclonal antibodies using melanoma modified with Fas ligand
Int. Immunol.,
April 1, 2008;
20(4):
525 - 534.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-Y. Wang, E. Racila, R. P. Taylor, and G. J. Weiner
NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement
Blood,
February 1, 2008;
111(3):
1456 - 1463.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Daniel, B. Yang, D. A. Lawrence, K. Totpal, I. Balter, W. P. Lee, A. Gogineni, M. J. Cole, S. F. Yee, S. Ross, et al.
Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts
Blood,
December 1, 2007;
110(12):
4037 - 4046.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Macor, C. Tripodo, S. Zorzet, E. Piovan, F. Bossi, R. Marzari, A. Amadori, and F. Tedesco
In vivo Targeting of Human Neutralizing Antibodies against CD55 and CD59 to Lymphoma Cells Increases the Antitumor Activity of Rituximab
Cancer Res.,
November 1, 2007;
67(21):
10556 - 10563.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Li, M. E. Williams, J. B. Cousar, A. W. Pawluczkowycz, M. A. Lindorfer, and R. P. Taylor
Rituximab-CD20 Complexes Are Shaved from Z138 Mantle Cell Lymphoma Cells in Intravenous and Subcutaneous SCID Mouse Models
J. Immunol.,
September 15, 2007;
179(6):
4263 - 4271.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Chentouf, S. Ghannam, C. Bes, S. Troadec, M. Cerutti, and T. Chardes
Recombinant Anti-CD4 Antibody 13B8.2 Blocks Membrane-Proximal Events by Excluding the Zap70 Molecule and Downstream Targets SLP-76, PLC{gamma}1, and Vav-1 from the CD4-Segregated Brij 98 Detergent-Resistant Raft Domains
J. Immunol.,
July 1, 2007;
179(1):
409 - 420.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Cittera, M. Leidi, C. Buracchi, F. Pasqualini, S. Sozzani, A. Vecchi, J. D. Waterfield, M. Introna, and J. Golay
The CCL3 Family of Chemokines and Innate Immunity Cooperate In Vivo in the Eradication of an Established Lymphoma Xenograft by Rituximab
J. Immunol.,
May 15, 2007;
178(10):
6616 - 6623.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G. Maloney
Follicular NHL: From Antibodies and Vaccines to Graft-versus-Lymphoma Effects
Hematology,
January 1, 2007;
2007(1):
226 - 232.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Umana, E. Moessner, P. Bruenker, G. Unsin, U. Puentener, T. Suter, R. Grau, C. Schmidt, C. Gerdes, A. Nopora, et al.
Novel 3rd Generation Humanized Type II CD20 Antibody with Glycoengineered Fc and Modified Elbow Hinge for Enhanced ADCC and Superior Apoptosis Induction.
Blood (ASH Annual Meeting Abstracts),
November 16, 2006;
108(11):
229 - 229.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. A. Bowles, S.-Y. Wang, B. K. Link, B. Allan, G. Beuerlein, M.-A. Campbell, D. Marquis, B. Ondek, J. E. Wooldridge, B. J. Smith, et al.
Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab
Blood,
October 15, 2006;
108(8):
2648 - 2654.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. T. Rankin, M.-C. Veri, S. Gorlatov, N. Tuaillon, S. Burke, L. Huang, H. D. Inzunza, H. Li, S. Thomas, S. Johnson, et al.
CD32B, the human inhibitory Fc-{gamma} receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma
Blood,
October 1, 2006;
108(7):
2384 - 2391.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Alfonso-Perez, S. Lopez-Giral, N. E. Quintana, J. Loscertales, P. Martin-Jimenez, and C. Munoz
Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia
J. Leukoc. Biol.,
June 1, 2006;
79(6):
1157 - 1165.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Provencio, S. Cerdeira, F. Bonilla, A. Sanchez, and P. Espana
Rapid-infusion rituximab in lymphoma treatment
Ann. Onc.,
June 1, 2006;
17(6):
1027 - 1028.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Macor, D. Mezzanzanica, C. Cossetti, P. Alberti, M. Figini, S. Canevari, and F. Tedesco
Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma.
Cancer Res.,
April 1, 2006;
66(7):
3876 - 3883.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. V. Beum, A. D. Kennedy, M. E. Williams, M. A. Lindorfer, and R. P. Taylor
The Shaving Reaction: Rituximab/CD20 Complexes Are Removed from Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia Cells by THP-1 Monocytes
J. Immunol.,
February 15, 2006;
176(4):
2600 - 2609.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. F. Israel, M. Gulley, S. Elmore, S. Ferrini, W.-h. Feng, and S. C. Kenney
Anti-CD70 antibodies: a potential treatment for EBV+ CD70-expressing lymphomas
Mol. Cancer Ther.,
December 1, 2005;
4(12):
2037 - 2044.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E A Clark and J A Ledbetter
How does B cell depletion therapy work, and how can it be improved?
Ann Rheum Dis,
November 1, 2005;
64(suppl_4):
iv77 - iv80.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Feugier, A. Van Hoof, C. Sebban, P. Solal-Celigny, R. Bouabdallah, C. Ferme, B. Christian, E. Lepage, H. Tilly, F. Morschhauser, et al.
Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte
J. Clin. Oncol.,
June 20, 2005;
23(18):
4117 - 4126.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Nagata, T. Ise, M. Onda, K. Nakamura, M. Ho, A. Raubitschek, and I. H. Pastan
Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy
PNAS,
May 31, 2005;
102(22):
7946 - 7951.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Carter and C. F. McDonagh
Designer Antibody-Based Therapeutics for Oncology
Am. Assoc. Cancer Res. Educ. Book,
April 1, 2005;
2005(1):
147 - 154.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Horning, A. Younes, V. Jain, S. Kroll, J. Lucas, D. Podoloff, and M. Goris
Efficacy and Safety of Tositumomab and Iodine-131 Tositumomab (Bexxar) in B-Cell Lymphoma, Progressive After Rituximab
J. Clin. Oncol.,
February 1, 2005;
23(4):
712 - 719.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Friedberg
Unique Toxicities and Resistance Mechanisms Associated with Monoclonal Antibody Therapy
Hematology,
January 1, 2005;
2005(1):
329 - 334.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Sharkey and D. M. Goldenberg
Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies
J. Nucl. Med.,
January 1, 2005;
46(1_suppl):
115S - 127S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Cartron, H. Watier, J. Golay, and P. Solal-Celigny
From the bench to the bedside: ways to improve rituximab efficacy
Blood,
November 1, 2004;
104(9):
2635 - 2642.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Cragg, M. B. Bayne, A. L. Tutt, R. R. French, S. Beers, M. J. Glennie, and T. M. Illidge
A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells
Blood,
October 15, 2004;
104(8):
2540 - 2542.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Teeling, R. R. French, M. S. Cragg, J. van den Brakel, M. Pluyter, H. Huang, C. Chan, P. W. H. I. Parren, C. E. Hack, M. Dechant, et al.
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas
Blood,
September 15, 2004;
104(6):
1793 - 1800.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Olszewski and M. L. Grossbard
Empowering Targeted Therapy: Lessons from Rituximab
Sci. Signal.,
July 13, 2004;
2004(241):
pe30 - pe30.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Uchida, Y. Hamaguchi, J. A. Oliver, J. V. Ravetch, J. C. Poe, K. M. Haas, and T. F. Tedder
The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor-dependent Mechanisms during Anti-CD20 Antibody Immunotherapy
J. Exp. Med.,
June 21, 2004;
199(12):
1659 - 1669.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
